{"id":"W4200384155","doi":"10.1093/ofid/ofab466.701","title":"502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab","year":2021,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Interim analysis; Coronavirus disease 2019 (COVID-19); Randomization; Clinical trial; Relative risk; Disease; Confidence interval; Pathology; Infectious disease (medical specialty)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008638264,0.0003511561,0.001026562,0.0001863449,0.0001561298,0.0004245415,0.0003420447,0.0006455674,0.008836769],"category_scores_gemma":[0.0007310396,0.0001249866,0.000769829,0.0001408753,0.0002370953,0.0002612349,0.0001564247,0.0009771343,0.0009921337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003307182,"about_ca_system_score_gemma":0.0005407698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003115911,"about_ca_topic_score_gemma":0.0007502883,"domain_scores_codex":[0.999668,0.000162316,0.00003018095,0.00004275402,0.00004559013,0.00005112303],"domain_scores_gemma":[0.9996145,0.0001184182,0.0001051728,0.00002418236,0.00003230198,0.0001054213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5680262,0.01603281,0.00877064,0.002067307,0.001186197,0.0001741907,0.00007137327,0.001152589,0.04740889,0.0006739073,0.009668432,0.3447675],"study_design_scores_gemma":[0.5289983,0.3611426,0.06445845,0.0004788158,0.001783103,0.000614225,0.00005218991,0.002552759,0.01724195,0.0007000816,0.02193172,0.00004588811],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9624346,0.01640628,0.001647553,0.001376694,0.000647501,0.00273195,0.002549812,0.0002161252,0.01198955],"genre_scores_gemma":[0.9866941,0.002764566,0.001471469,0.001263942,0.0005922563,0.001411096,0.001925635,0.00001841386,0.003858521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008836769,"threshold_uncertainty_score":0.02956194,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04781342582594231,"score_gpt":0.3907940115901449,"score_spread":0.3429805857642025,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}